drugset / Trial / NCT00497731
AZD1152 in Patients With Advanced Solid Malignancies-Study 1
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 2-hour infusion every week and every 2 weeks in patients with advanced solid malignancies.
Timeline
- Start
- 2005-05
- Primary completion
- 2008-06
- Completion
- 2009-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | barasertib | Small molecule | — | Intravenous |